Antimicrobial Prophylaxis Practices for Patients with Hematologic Malignancies
Recommended Citation
Obioma JE, Abdallah N, Bahar T, Powell M, Shupp M. Antimicrobial Prophylaxis Practices for Patients with Hematologic Malignancies. Am J Health Syst Pharm 2025; 82:S358.
Document Type
Conference Proceeding
Publication Date
1-8-2025
Publication Title
Am J Health Syst Pharm
Abstract
Purpose: Antimicrobial prophylaxis is recommended for patients at high risk of infection, particularly those undergoing cytotoxic chemotherapy. Hematologic malignancies develop in blood-forming tissues or immune cells of the bone marrow and lymph nodes. At Henry Ford Health, there is an absence of standardized guidelines for antimicrobial prophylaxis in patients with hematologic malignancies. This study aims to outline the current antimicrobial prophylaxis practices for patients with hematologic malignances, with the goal of developing a standardized policy at Henry Ford Health to enhance clinical outcomes in patients at high risk for infection. Methods: This is an IRB-approved retrospective cohort study that will look at patients from August 2022 to August 2024 who received prophylaxis for Pneumocystis jirovecii pneumonia (PJP) cytomegalovirus, varicella zoster virus/Herpes simplex virus (HSV), bacterial, and fungal infections. Patients over the age of 18 who received treatment for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, lymphoma, and aplastic anemia will be included. Patients will be excluded if they are prescribed antibiotics for an acute infection or are receiving prophylaxis unrelated to their malignancy (i.e. solid organ transplant, HIV infection). The primary outcome of this study is to determine the most appropriate antimicrobial agents for infection prophylaxis in various hematologic malignancies in order to create a standardized policy at Henry Ford Hospital. Secondary outcomes are to determine optimal duration of prophylaxis and to develop tailored prophylactic strategies based on patient risk factors and disease characteristics. All data collected will be analyzed using descriptive statistics. The planned sample size is 200 patients.
Volume
82
First Page
S358
